Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
  1. Home
  3. Beyond The Status Quo: When Disease Volume And Metastatic Timing Are Not Enough To Personalize Treatment In Mhspc.
  1. Home
  3. Beyond The Status Quo: When Disease Volume And Metastatic Timing Are Not Enough To Personalize Treatment In Mhspc.

Related Experiment Video

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.1K

Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.

Ángel Borque-Fernando1, Teresa Alonso-Gordoa2, María José Juan-Fita3

  • 1Urology Department, Hospital Universitario Miguel Servet, IIS-Aragón, Zaragoza, Spain.

Future Oncology (London, England)
|March 3, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Treatment intensification for metastatic hormone-sensitive prostate cancer (mHSPC) needs better prognostic factors beyond disease volume. Personalized medicine using biomarkers will optimize doublet and triplet regimens for improved patient outcomes.

Keywords:
Metastatic hormone sensitive prostate cancerdisease volumemetachronouspersonalized treatmentprognosissynchronoustreatment intensification

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K

Related Experiment Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.1K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Metastatic hormone-sensitive prostate cancer (mHSPC) treatment intensification is complex.
  • Current prognostic factors like disease volume and metastatic timing are insufficient for personalized therapy.

Purpose of the Study:

  • To review the limitations of current prognostic factors in mHSPC.
  • To highlight the importance of a personalized approach using diverse prognostic indicators.
  • To propose multimodal strategies and predictive biomarkers for optimizing treatment selection.

Main Methods:

  • Review of existing literature on prognostic indicators in mHSPC.
  • Examination of clinical, analytical, pathological, molecular, and imaging data.
  • Analysis of current treatment algorithms and their limitations.

Main Results:

  • Disease volume and metastatic timing are inadequate sole prognosticators.
  • A personalized approach integrating multiple prognostic factors is crucial.
  • Predictive biomarkers are needed to guide therapy selection between doublet and triplet regimens.

Conclusions:

  • Individualized therapy selection in mHSPC requires moving beyond conventional classifications.
  • Emerging biomarkers hold promise for precision treatment in mHSPC.
  • Future clinical trials should incorporate novel biomarkers to refine treatment strategies.